Abstract:Objective:We conducted a real-world multi-center clinical study with a large sample size to comprehensively evaluate the performance of three commercial hepatitis C virus (HCV) core antigen assays. The study aimed to evaluate the performance for their use in HCV infection screening, and to provide clues for further improving the sensitivity and specificity of the assays.Methods:Key performance indicators including the lower limit of detection (LOD), diagnostic sensitivity, and specificity of three HCV antigen assays (the Architect, Laibo, and ChemClin HCV core antigen assays) were evaluated using commercial seroconversion panels reflecting early HCV infection and clinical routine serum samples of outpatients and inpatients from 3 tertiary hospitals from January 2018 to April 2022. Factors that affect the performance indicators were further investigated.Results:The window period for detecting HCV infection with the three antigen assays was equal to or slightly longer than that of the RNA assay, but all are shorter than that of the anti-HCV assay. There was a good linear positive correlation between HCV core antigen and HCV RNA levels in treatment naive patients with hepatitis C ( r=0.90, P<0.01). For the most common genotype 1b strain in China, the LOD of the three HCV assays were equivalent to 531 IU/ml (Architect), 3,698 IU/mL (Laibo), and 4,624 IU/mL (ChemClin) HCV RNA, respectively. Due to the skewed distribution of HCV RNA levels in treatment-naive hepatitis C patients, more than 95% of the patients had viral loads higher than 6 166 IU/ml. Therefore, the three HCV antigens assays still maintained a satisfactory diagnostic sensitivity (94.33%-99.40%). Among 54 immunodeficient patients (leukemia patients) with HCV infection, 9% (5/54) had negative anti-HCV results, while the HCV antigen assays found all these infectors. Through further experiments, we revealed the amino acid polymorphism in the core region of genotype 3 strain impaired the sensitivity of all three HCV antigen assays. In addition, the sensitivity of the two domestic assays was impaired by anti-HCV antibodies in the serum. The specificity of HCV antigen assays for diagnosing hepatitis C is 99.94% to 99.98%. The rheumatoid factors, autoantibodies, and other unknown interference substances can lead to a small number of low level, "false positive" antigen results. Conclusions:HCV core antigen assay may be used as a satisfactory approach of infection screening, especially for the immunodeficient patents. However, the sensitivity and specificity of the assays are influenced by multiple factors, which should be further improved.

Traceability, Reproducibility and Clinical Evaluation of Sansure Realtime HCV RNA Assay

A Novel Real-Time Reverse Transcription-Polymerase Chain Reaction Assay with Partially Double-Stranded Linear DNA Probe for Sensitive Detection of Hepatitis C Viral RNA.

The Tracability and Uniform Unit of Hepatitis C Virus RNA Quantification by Domestic Made Real-Time Fluorescence Quantitative PCR Method

Progress and challenges in the laboratory diagnosis of hepatitis C virus

A Chromogenic In Situ Hybridization (CISH) Assay for Detection of HBV RNA, DNA, and cccDNA in Liver Tissue

Evaluation of a Novel Fully Automated Real-Time PCR Assay for Hepatitis B Virus DNA Quantification

Clinical diagnostic performance of light-initiated chemiluminescent assay compared with the Architect chemiluminescence immunoassay for detection of HCV antibody.

Evaluation of clinical utility of a novel method for quantitative detection of hepatitis B virus RNA

Establishment of Quality Control System for Domestic Hepatitis C Diagnostic Reagents

A multi-center performance evaluation of different hepatitis C virus core antigen assays for clinical infection screening

Evaluation of reverse transcription-polymerase chain reaction and simultaneous amplification and testing for quantitative detection of serum hepatitis B virus RNA

Development of a Multiplex Real-Time PCR Assay for the Detection of Treponema pallidum, HCV, HIV-1, and HBV

Establishment of a Novel One-Step Reverse Transcription Loop-Mediated Isothermal Amplification Assay for Rapid Identification of RNA from the Severe Fever with Thrombocytopenia Syndrome Virus.

Biosensor‐based multiple cross displacement amplification platform for visual and rapid identification of hepatitis C virus

Analysis of the Results of External Quality Assessment for Hepatitis C Virus RNA Tests

Evaluation of a novel domestic hepatitis B viral DNA quantitative fluorescence diagnostic kit

Design and validation of a clinical DNA sequencing assay for drug-resistance genes in hepatitis B virus

A Standardized Assay for the Quantitative Detection of Serum HBV RNA in Chronic Hepatitis B Patients.

Fully automated rapid quantification of Hepatitis C Virus RNA in human plasma and serum by integrated on-chip RT-qPCR and capillary electrophoresis

Establishment and methodological evaluation of a chemiluminescence assay for detection of anti‐envelope protein (E1, E2) antibodies in the serum of hepatitis C virus‐infected patients